The Biotechnology Innovation Organization (BIO) opposed a proposed Office of Management and Budget (OMB) rule governing federal financial assistance, arguing it would destabilize biomedical research funding and delay patient access to novel therapies. BIO said the proposal increases the risk of “at will” grant termination and shifts emphasis away from merit-based peer review toward administration priorities. BIO’s comments warn that added uncertainty and administrative complexity could reduce academic participation and weaken downstream private investment, partnerships, and therapy development. The pushback comes alongside an OMB framing that aims to improve transparency and oversight of federal awards, but industry groups are contesting whether the compliance model undermines scientific governance. The next regulatory steps—comment cycles and potential revisions—could materially affect how quickly universities and startups secure early translational support.